Citigroup
MENS

Citigroup’s Jyong Biotech MENS Stock Holding History

Citigroup’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.99K Sell
2,787
-8,109
-74% -$19.8K ﹤0.01% 5212
2025
Q4 		$43K Buy
+10,896
New +$385K ﹤0.01% 4626

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup's MENS Position: Q1 2026 in Review

Citigroup reduced its Jyong Biotech (MENS) stake by 74% in Q1 2026, selling an estimated $19.8K and leaving 2,787 shares worth $5.99K. The position accounts for ﹤0.01% of the portfolio, ranked #5212.

Citigroup first reported a position in MENS in Q4 2025 and has held it in 2 quarters since. The position peaked at $43K in Q4 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • Citigroup held 2,787 shares of Jyong Biotech worth $5.99K as of Q1 2026.
  • Citigroup sold 8,109 Jyong Biotech shares in Q1 2026, an estimated $19.8K.
  • Jyong Biotech made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5212 holding.
  • Citigroup first reported a position in Jyong Biotech in Q4 2025 and has held it in 2 quarters since.
  • Citigroup's Jyong Biotech position peaked at $43K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.